부광약품, 자회사 콘테라파마 ‘RNA 사업부’ 스핀오프…밸류업 드라이브

Contrafiama's spinoff of its RNA platform represents a strategic pivot to unlock value in next-generation therapeutics while enabling independent funding and rapid advancement of RNA-based therapies for rare genetic diseases. This move reflects the growing biotech trend of creating specialized entities to accelerate high-risk, high-reward therapeutic programs through focused investment and partnerships.